Lowering LDL cholesterol methods
Pro Research Analysisby 
Searched over 200M research papers
Statins as First-Line LDL Cholesterol Lowering Therapy
Statins are the primary and most widely recommended treatment for lowering LDL cholesterol (LDL-C). They work by inhibiting the enzyme HMG-CoA reductase, which is crucial for cholesterol production in the liver. Statins have been shown to significantly reduce LDL-C levels and lower the risk of cardiovascular events in both younger and older adults, making them the cornerstone of LDL-C management for most patients at risk of atherosclerotic cardiovascular disease (ASCVD) Luo2022Brautbar2011Pirillo2020+3 MORE.
Nonstatin LDL Cholesterol Lowering Agents
Ezetimibe
Ezetimibe is often used as an add-on therapy to statins or as an alternative for patients who are intolerant to statins. It works by blocking cholesterol absorption in the intestine, leading to further reductions in LDL-C when combined with statins. Ezetimibe has demonstrated additional cardiovascular benefits when added to statin therapy, especially in high-risk patients Toth2022Luo2022Brautbar2011+7 MORE.
PCSK9 Inhibitors
PCSK9 inhibitors, such as evolocumab and alirocumab, are injectable monoclonal antibodies that significantly lower LDL-C by increasing the liver’s ability to remove LDL from the blood. These agents are particularly effective when added to maximally tolerated statin therapy and are recommended for patients who need further LDL-C reduction or are statin-intolerant. Clinical trials have shown that PCSK9 inhibitors can achieve very low LDL-C levels and further reduce cardiovascular events without major safety concerns Toth2022Luo2022Brautbar2011+6 MORE.
Bempedoic Acid and Other Emerging Therapies
Bempedoic acid, alone or in combination with ezetimibe, is a newer oral agent that inhibits cholesterol synthesis upstream of statins. It is useful for patients who cannot tolerate statins or need additional LDL-C lowering. Other emerging therapies include inclisiran, a small-interfering RNA that targets PCSK9 production, and ATP-citrate lyase inhibitors, which are under investigation for their LDL-C lowering effects Toth2022Luo2022Malick2025+2 MORE.
Bile Acid Sequestrants, Niacin, and Fibrates
Older nonstatin agents like bile acid sequestrants, niacin, and fibrates can lower LDL-C, but their use is now limited due to less robust cardiovascular outcome data and potential side effects. They may be considered in select cases where other therapies are not suitable Luo2022Brautbar2011Pirillo2020+1 MORE.
Combination and Alternative LDL Cholesterol Lowering Strategies
Combining moderate-intensity statins with ezetimibe or using a treat-to-target approach can be as effective as high-intensity statin therapy for reducing LDL-C and cardiovascular events. These alternative strategies may also reduce the risk of new-onset diabetes and therapy intolerance, making them suitable for patients who experience side effects with high-intensity statins Malick2025Lee2024.
LDL Cholesterol Lowering in Older Adults
Lowering LDL-C is effective in reducing major vascular events in patients aged 75 years and older, with benefits similar to those seen in younger patients. Both statin and nonstatin therapies are effective and safe in this population, supporting guideline recommendations for their use in older adults Gencer2020Badalyan2023.
Achieving Aggressive LDL Cholesterol Targets
Recent guidelines emphasize the importance of achieving very low LDL-C levels, especially in high-risk individuals. Combination therapy with statins, ezetimibe, and/or PCSK9 inhibitors makes it possible to reach these aggressive targets, leading to further reductions in cardiovascular risk without significant safety concerns over several years of follow-up Toth2022Luo2022Brautbar2011+6 MORE.
Conclusion
Lowering LDL cholesterol is essential for reducing cardiovascular risk. Statins remain the first-line therapy, but nonstatin agents like ezetimibe, PCSK9 inhibitors, and bempedoic acid provide effective options for patients who need additional LDL-C reduction or cannot tolerate statins. Combination and alternative strategies are effective and safe, including in older adults. Achieving lower LDL-C targets with these therapies leads to greater cardiovascular protection, supporting their use in clinical practice.
Sources and full results
Most relevant research papers on this topic